1. Signaling Pathways
  2. Immunology/Inflammation
  3. Interleukin Related

Interleukin Related

Interleukins are a group of cytokines (secreted proteins and signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells. Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.

Interleukin Related Related Products (52):

Cat. No. Product Name Effect Purity
  • HY-10964
    Vadimezan Activator 99.81%
    Vadimezan (ASA-404; DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines.
  • HY-B0240
    Disulfiram Inhibitor 98.67%
    Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells[1-4].
  • HY-117287
    BMS-986165 Inhibitor 99.76%
    BMS-986165 is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. BMS-986165 inhibits IL-12/23 and type I IFN pathways.
  • HY-B0879A
    Suramin sodium salt Inhibitor 99.93%
    Suramin sodium salt (Suramin hexasodium salt), a polysulfonated naphthylurea, is a potent competitive DNA topoisomerase II inhibitor with an IC50 of 5 μM. Suramin sodium salt inhibits IL-4 with an IC50 of 55-70 μM. Suramin sodium salt has antiproliferative, anticancer, and anti-HIV activities and prevents binding of a variety of growth factors to their respective receptors.
  • HY-14644
    Apilimod Inhibitor 99.61%
    Apilimod is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively.
  • HY-P9917
    Tocilizumab Antagonist 98.80%
    Tocilizumab (Anti-Human IL6R) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R) is approved for the treatment of rheumatoid arthritis in Europe and the United States[1].
  • HY-N0600
    Ginsenoside F3 99.84%
    Ginsenoside F3, a component of PPTGs (an minor saponin in the leaves of Panax ginseng), has immunoenhancing activity by regulating production and gene expression of type 1 cytokines (IL-2, IFN-gamma) and type 2 cytokines (IL-4 and IL-10).
  • HY-15614
    SC144 Inhibitor 98.05%
    SC144 is the first-in-class orally active small-molecule gp130 inhibitor; inhibits cell growth in a panel of human ovarian cancer cell lines with IC50 values in a submicromolar range.
  • HY-N0283
    Diacerein Inhibitor 98.78%
    Diacerein (Diacerhein), a interleukin-1 beta inhibitor, is a slow-acting medicine of the class anthraquinone used to treat joint diseases.
  • HY-N0604
    Ginsenoside Rh1 Inhibitor >98.0%
    Ginsenoside Rh1 (Prosapogenin A2; Sanchinoside B2; Sanchinoside Rh1) is isolated from the root of Panax Ginseng. Ginsenoside Rh1 inhibits the expression of PPAR-γ, TNF-α, IL-6, and IL-1β.
  • HY-114775
    RCGD423 Modulator 99.34%
    RCGD423 is a gp130 modulator, which prevents articular cartilage degeneration and promotes repair.
  • HY-15982
    APY0201 Inhibitor >98.0%
    APY0201 is a potent PIKfyve inhibitor, which inhibits the conversion of PtdIns3P to PtdIns(3,5)P2 in the presence of in the presence of [33P]ATP with an IC50 of 5.2 nM. APY0201 also inhibits IL-12/IL-23 production.
  • HY-107390A
    AX-024 hydrochloride Inhibitor 99.29%
    AX-024 hydrochloride is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. AX-024 hydrochloride modulates cell signaling by targeting SH3 domains. AX-024 hydrochloride has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
  • HY-14908
    Vidofludimus Inhibitor 99.14%
    Vidofludimus(4SC-101; SC12267) is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.
  • HY-107390
    AX-024 Inhibitor >98.0%
    AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. AX-024 modulates cell signaling by targeting SH3 domains. AX-024 has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
  • HY-N0722
    Neochlorogenic acid Inhibitor 99.46%
    Neochlorogenic acid is a natural polyphenolic compound found in dried fruits and other plants. Neochlorogenic acid inhibits the production of TNF-α and IL-1β. Neochlorogenic acid suppresses iNOS and COX-2 protein expression. Neochlorogenic acid also inhibits phosphorylated NF-κB p65 and p38 MAPK activation.
  • HY-101860
    GIBH-130 Inhibitor 99.82%
    GIBH-130 is an effective inhibitor of neuroinflammation. GIBH-130 significantly suppresses the IL-1β secretion by activated microglia (IC50=3.4 nM).
  • HY-15898
    Y-320 Inhibitor 99.07%
    Y-320 is a new phenylpyrazoleanilide immunomodulator; inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 values of 20 to 60 nM.
  • HY-B0667
    Balsalazide Inhibitor 99.20%
    Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.
  • HY-17002
    Suplatast Tosilate Inhibitor 99.26%
    Suplatast Tosilate (IPD 1151T) is a Th2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.